Mankind Pharma partners with BDR Pharma to distribute Baricitinib in India
BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CDSCO
Zydus Cadila gets CDSCO nod for clinical trials of antibodies cocktail to treat COVID-19: Sources
These antibodies are made by cloning unique white blood cells
Cipla to market Roche’s antibody cocktail pan-India, first batch currently available
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in…
Lilly signs voluntary licensing agreement with Natco for baricitinib
Lilly had also signed voluntary license agreements with Cipla, Lupin, Sun Pharma, Dr Reddy’s, MSN Labs and Torrent Pharma
SEC recommends phase II/III clinical trials of Covaxin on 2-18 year-olds
The trial will be conducted on 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of…
Cipla signs licensing deal with Lilly to manufacture and commercialise baricitinib in India
Baricitinib was issued a restricted emergency use approval by CDSCO to treat COVID-19
DCGI nod for anti-COVID 19 drug developed by DRDO
Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental…
Roche’s antibody cocktail for COVID-19 may face affordability issues in India: GlobalData
Considering that it is a combination of two recombinant human immunoglobulin G-1 (IgG1) monoclonal antibodies, it is expected to…
Roche gets EUA in India for antibody cocktail (Casirivimab and Imdevimab) to treat COVID-19
Partners with Cipla for pan-India distribution
Eli Lilly accelerates baricitinib’s availability in India
Lilly is working with the Indian government to provide baricitinib donations in conjunction with the permission